
Publication
Government of Alberta launches nuclear energy engagement
On August 25, 2025, the Government of Alberta publicly re-affirmed its interest in nuclear energy with the launch of its Nuclear Energy Engagement (the Engagement).
Author:
Canada | Publication | June 2020
A detailed table outlining the various programs available in Ontario are listed below. If you would like to discuss your eligibility for any of these programs, please do not hesitate to contact a member of our team.
Description | Eligibility | Application details |
---|---|---|
|
|
|
Ontario Together Fund
Description | Eligibility | Application details |
---|---|---|
|
|
|
Description | Eligibility | Application details |
---|---|---|
|
|
|
Description | Eligibility | Application details |
---|---|---|
|
|
|
Description | Eligibility | Application details |
---|---|---|
|
|
|
Description | Eligibility | Application details |
---|---|---|
|
|
|
Description | Eligibility | Application details |
---|---|---|
|
|
|
Description | Eligibility | Application details |
---|---|---|
|
|
|
Description | Eligibility | Application details |
---|---|---|
|
|
|
Description | Eligibility | Application details |
---|---|---|
|
|
|
Description | Eligibility | Application details |
---|---|---|
|
|
|
Description | Eligibility | Application details |
---|---|---|
|
|
|
Description | Eligibility | Application details |
---|---|---|
|
|
|
Description | Eligibility | Application details |
---|---|---|
|
|
|
Publication
On August 25, 2025, the Government of Alberta publicly re-affirmed its interest in nuclear energy with the launch of its Nuclear Energy Engagement (the Engagement).
Publication
Health Canada has proposed a major change to the regulation of biosimilar drugs that may accelerate biologic patent litigation in Canada. Following the lead of other jurisdictions, Health Canada has proposed that biosimilar manufacturers no longer be required to conduct phase 3 clinical trials to enter the Canadian market.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2025